Premium
Leuprorelin acetate blood levels and dialysance after the administration of sustained‐release leuprorelin acetate in a dialysis case complicated by prostate cancer
Author(s) -
Saruki Kazuhisa,
Sekihara Tetsuo,
Mashimo Masamichi,
Matsuo Hidenori,
Sekiguchi Hiroyuki
Publication year - 1998
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/(sici)1097-0045(19980215)34:3<191::aid-pros6>3.0.co;2-l
Subject(s) - leuprorelin , medicine , prostate cancer , urology , dialysis , prostate , cancer , surgery , hormone , luteinizing hormone , gonadotropin releasing hormone
BACKGROUND The objective of this study is to determine whether in a dialysis patient with prostate cancer leuprorelin acetate blood levels were abnormally high or low due to kidney failure or because of dialysis. METHODS Sustained‐release leuprorelin acetate 3.75 mg was given every 4 weeks for prostate cancer in a 79‐year‐old dialysis patient. Changes in serum level of leuprorelin acetate in this patient were measured before and after dialysis. RESULTS Leuprorelin acetate appeared to have a dialysance close to that of vitamin B 12 , which has a similar molecular weight. The amount dialyzed did not exceed 8.3% of the amount released per day. Mean blood levels of leuprorelin acetate, as measured in this patient, were higher (0.64 to 1.31 ng/ml) than those in prostate cancer patients with normal kidney function (mean ± SD, 0.24 ± 0.12 to 0.50 ± 0.32 ng/ml). CONCLUSIONS Sustained‐release leuprorelin acetate can be used safely in dialysis patients with prostate cancer. Prostate 34:191–194, 1998. © 1998 Wiley‐Liss, Inc.